News | Thrombectomy Devices | February 12, 2019

JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis

Study presented at CIRSE 2018 demonstrated efficacy in single-session setting without post-procedural lytic infusion

JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis

February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) explored the safety and efficacy of the JETI-8 Peripheral Thrombectomy System for the treatment of acute deep vein thrombosis (DVT). The study, presented by Jean Cournoyer-Rodrigue, M.D., CHUM Research Center, Montreal, showed 83 percent technical success.

The JETi Thrombectomy System is a device that breaks-up and removes thrombus from the coronary and peripheral vasculature, incorporating a powerful internal jet technology that macerates thrombus just inside its mouth and lubricates the proximally flowing aspirate. The device has a desirable safety profile, allows for single-session treatment potential with or without lytics, has U.S. Food and Drug Administration (FDA) 510K clearance and CE Mark.

Jeti was tested in 23 venous thromboembolism (VTE) procedures, resulting in 83 percent technical success, defined as restoration of integrate flow with the elimination of any obstructing lesion, without overnight CDT. In addition, 4 out of 23 procedures required post-procedure lytic infusion before achieving procedural and technical success, with overnight CDT. Current thrombectomy market leaders such as Angiojet have only demonstrated single-session success of 34 percent in their seminal Pearl registry, according to Walk Vascular. No complication, hemolysis or blood transfusion was reported. Mean thrombus removal across all patients was 93 percent.

For more information: www.cirse.org

Related Content

News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
Subscribe Now